BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Celsense Inc. is Issued Patent for MRI Cell Tracking Product


12/22/2011 8:28:30 AM

Pittsburgh, PA (PRWEB) December 22, 2011 -- Celsense, Inc., announced today that it has received a Notice of Allowance for US Patent Application 10/586,015 with claims covering its MRI cell tracking product, Cell Sense.

Cell Sense is a perfluorocarbon tracer agent used to label cells ex vivo, making them detectable in vivo after transplantation using magnetic resonance imaging (“MRI”). Invented by Eric Ahrens at Carnegie Mellon University, Cell Sense can be used to non-invasively image the administration, migration, and persistence of cells transplanted for therapeutic or diagnostic purposes using MRI. The use of Cell Sense was first reported in the journal Nature Biotechnology in 2005.

Cell Sense is currently available for use in preclinical research and human clinical trials. The first clinical use of Cell Sense is in combination with an autologous dendritic cell vaccine used to treat colorectal cancer; the trial was authorized by the US FDA in May of 2011. It is contemplated that patient recruitment will commence in early 2012.

The patent, ‘Cellular labeling for nuclear magnetic resonance techniques,” includes a broad set of claims covering methods and compositions for the use of perfluorocarbon tracer agents to detect transplanted cells in MRI and nuclear magnetic resonance (NMR). Ropes and Gray LLP acted as counsel to Carnegie Mellon University and Celsense, Inc., in the prosecution of the patent.

"We are delighted to add this patent to our growing intellectual property portfolio and to extend our leadership position in cellular and molecular imaging tools," said Charlie O'Hanlon, President and CEO of Celsense.

About Celsense, Inc.

Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells using in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies and medical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->